FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:PKD1-PIEZO1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: PKD1-PIEZO1
FusionPDB ID: 65677
FusionGDB2.0 ID: 65677
HgeneTgene
Gene symbol

PKD1

PIEZO1

Gene ID

5310

9780

Gene namepolycystin 1, transient receptor potential channel interactingpiezo type mechanosensitive ion channel component 1
SynonymsPBP|PC1|Pc-1|TRPP1DHS|FAM38A|LMPH3|LMPHM6|Mib
Cytomap

16p13.3

16q24.3

Type of geneprotein-codingprotein-coding
Descriptionpolycystin-1autosomal dominant polycystic kidney disease 1 proteinpolycystic kidney disease 1 (autosomal dominant)polycystic kidney disease-associated proteintransient receptor potential cation channel, subfamily P, member 1piezo-type mechanosensitive ion channel component 1family with sequence similarity 38, member Amembrane protein induced by beta-amyloid treatment
Modification date2020031520200313
UniProtAcc.

Q92508

Main function of 5'-partner protein: FUNCTION: Pore-forming subunit of a mechanosensitive non-specific cation channel (PubMed:23479567, PubMed:23695678). Generates currents characterized by a linear current-voltage relationship that are sensitive to ruthenium red and gadolinium. Plays a key role in epithelial cell adhesion by maintaining integrin activation through R-Ras recruitment to the ER, most probably in its activated state, and subsequent stimulation of calpain signaling (PubMed:20016066). In the kidney, may contribute to the detection of intraluminal pressure changes and to urine flow sensing. Acts as shear-stress sensor that promotes endothelial cell organization and alignment in the direction of blood flow through calpain activation (PubMed:25119035). Plays a key role in blood vessel formation and vascular structure in both development and adult physiology (By similarity). Acts as sensor of phosphatidylserine (PS) flipping at the plasma membrane and governs morphogenesis of muscle cells. In myoblasts, flippase-mediated PS enrichment at the inner leaflet of plasma membrane triggers channel activation and Ca2+ influx followed by Rho GTPases signal transduction, leading to assembly of cortical actomyosin fibers and myotube formation. {ECO:0000250|UniProtKB:E2JF22, ECO:0000269|PubMed:20016066, ECO:0000269|PubMed:23479567, ECO:0000269|PubMed:23695678, ECO:0000269|PubMed:25119035, ECO:0000269|PubMed:29799007}.
Ensembl transtripts involved in fusion geneENST idsENST00000262304, ENST00000423118, 
ENST00000561991, 
ENST00000327397, 
ENST00000301015, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score14 X 13 X 9=16386 X 4 X 2=48
# samples 146
** MAII scorelog2(14/1638*10)=-3.54843662469604
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(6/48*10)=0.321928094887362
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0
Fusion gene context

PubMed: PKD1 [Title/Abstract] AND PIEZO1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: PKD1 [Title/Abstract] AND PIEZO1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)PKD1(2155865)-PIEZO1(88802816), # samples:1
Anticipated loss of major functional domain due to fusion event.PKD1-PIEZO1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PKD1-PIEZO1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PKD1-PIEZO1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
PKD1-PIEZO1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgenePKD1

GO:0045737

positive regulation of cyclin-dependent protein serine/threonine kinase activity

16311606

HgenePKD1

GO:0045944

positive regulation of transcription by RNA polymerase II

16311606

HgenePKD1

GO:0048754

branching morphogenesis of an epithelial tube

12482949

HgenePKD1

GO:0051290

protein heterotetramerization

30093605

HgenePKD1

GO:0061136

regulation of proteasomal protein catabolic process

23001567

HgenePKD1

GO:0198738

cell-cell signaling by wnt

27214281

HgenePKD1

GO:2000045

regulation of G1/S transition of mitotic cell cycle

16311606



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr16:2155865/chr16:88802816)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across PKD1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across PIEZO1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000423118PKD1chr162155865-ENST00000301015PIEZO1chr1688802816-146018072209143414710
ENST00000262304PKD1chr162155865-ENST00000301015PIEZO1chr1688802816-146018072209143414710

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000423118ENST00000301015PKD1chr162155865-PIEZO1chr1688802816-0.0021425940.9978574
ENST00000262304ENST00000301015PKD1chr162155865-PIEZO1chr1688802816-0.0021425940.9978574

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for PKD1-PIEZO1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
PKD1chr162155865PIEZO1chr168880281680722621IEYSLALVTVLNEVWSITYHSWLTFV

Top

Potential FusionNeoAntigen Information of PKD1-PIEZO1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
PKD1-PIEZO1_2155865_88802816.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
PKD1-PIEZO1chr162155865chr16888028168072HLA-B57:01VTVLNEVW0.99970.9903715
PKD1-PIEZO1chr162155865chr16888028168072HLA-B18:01NEVWSITY0.99940.75991119
PKD1-PIEZO1chr162155865chr16888028168072HLA-B58:02VTVLNEVW0.99920.9875715
PKD1-PIEZO1chr162155865chr16888028168072HLA-B58:01VTVLNEVW0.99910.9836715
PKD1-PIEZO1chr162155865chr16888028168072HLA-B57:03VTVLNEVW0.99870.9937715
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:22ALVTVLNEV0.99750.7327514
PKD1-PIEZO1chr162155865chr16888028168072HLA-B58:01LVTVLNEVW0.99750.9893615
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:11ALVTVLNEV0.99570.7446514
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:27ALVTVLNEV0.99550.7763514
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:67ALVTVLNEV0.99550.711514
PKD1-PIEZO1chr162155865chr16888028168072HLA-B57:01LVTVLNEVW0.99550.9933615
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:30ALVTVLNEV0.99550.711514
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:24ALVTVLNEV0.99550.711514
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:13ALVTVLNEV0.99540.8553514
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:60ALVTVLNEV0.99530.7089514
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:21ALVTVLNEV0.99530.8117514
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:16ALVTVLNEV0.99520.6579514
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:38ALVTVLNEV0.99170.7095514
PKD1-PIEZO1chr162155865chr16888028168072HLA-B18:01NEVWSITYH0.99090.85321120
PKD1-PIEZO1chr162155865chr16888028168072HLA-B58:02LVTVLNEVW0.98870.9887615
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:19ALVTVLNEV0.98740.514514
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:04ALVTVLNEV0.98490.9046514
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:29ALVTVLNEV0.98140.7097514
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:35TVLNEVWSI0.97460.5471817
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:38TVLNEVWSI0.97250.6647817
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:21TVLNEVWSI0.97230.6294817
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:35ALVTVLNEV0.96560.7237514
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:17ALVTVLNEV0.96350.8003514
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:20ALVTVLNEV0.9580.716514
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:04TVLNEVWSI0.95790.5259817
PKD1-PIEZO1chr162155865chr16888028168072HLA-B57:03LVTVLNEVW0.95620.9973615
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:60TVLNEVWSI0.95430.5066817
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:11TVLNEVWSI0.95030.5332817
PKD1-PIEZO1chr162155865chr16888028168072HLA-B53:01LVTVLNEVW0.91730.7965615
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:27TVLNEVWSI0.88630.5144817
PKD1-PIEZO1chr162155865chr16888028168072HLA-A32:13TVLNEVWSI0.78120.9178817
PKD1-PIEZO1chr162155865chr16888028168072HLA-B13:02TVLNEVWSI0.32230.5689817
PKD1-PIEZO1chr162155865chr16888028168072HLA-B13:02ALVTVLNEV0.06650.954514
PKD1-PIEZO1chr162155865chr16888028168072HLA-B15:01VLNEVWSITY0.99970.8263919
PKD1-PIEZO1chr162155865chr16888028168072HLA-B57:01EVWSITYHSW0.99730.95681222
PKD1-PIEZO1chr162155865chr16888028168072HLA-B15:25VLNEVWSITY0.99260.8845919
PKD1-PIEZO1chr162155865chr16888028168072HLA-B15:02VLNEVWSITY0.9870.8955919
PKD1-PIEZO1chr162155865chr16888028168072HLA-A32:13EVWSITYHSW0.87790.93171222
PKD1-PIEZO1chr162155865chr16888028168072HLA-B57:01LALVTVLNEVW0.99980.9894415
PKD1-PIEZO1chr162155865chr16888028168072HLA-B44:03NEVWSITYHSW0.99970.9421122
PKD1-PIEZO1chr162155865chr16888028168072HLA-B58:01LALVTVLNEVW0.9990.9875415
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:22SLALVTVLNEV0.99530.8632314
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:02ALVTVLNEV0.99750.5788514
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:05ALVTVLNEV0.99710.7084514
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:07ALVTVLNEV0.99560.7091514
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:01ALVTVLNEV0.99550.711514
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:07TVLNEVWSI0.95960.5098817
PKD1-PIEZO1chr162155865chr16888028168072HLA-B15:07VLNEVWSITY0.99910.6027919
PKD1-PIEZO1chr162155865chr16888028168072HLA-B15:21VLNEVWSITY0.98620.8815919
PKD1-PIEZO1chr162155865chr16888028168072HLA-B15:04VLNEVWSITY0.97320.818919
PKD1-PIEZO1chr162155865chr16888028168072HLA-B15:05VLNEVWSITY0.93760.8532919
PKD1-PIEZO1chr162155865chr16888028168072HLA-B15:31VLNEVWSITY0.90510.8574919
PKD1-PIEZO1chr162155865chr16888028168072HLA-B57:10VTVLNEVW0.99970.9903715
PKD1-PIEZO1chr162155865chr16888028168072HLA-B18:07NEVWSITY0.99950.71591119
PKD1-PIEZO1chr162155865chr16888028168072HLA-B18:04NEVWSITY0.99950.77861119
PKD1-PIEZO1chr162155865chr16888028168072HLA-B18:08NEVWSITY0.99940.60671119
PKD1-PIEZO1chr162155865chr16888028168072HLA-B18:05NEVWSITY0.99940.75991119
PKD1-PIEZO1chr162155865chr16888028168072HLA-B57:04VTVLNEVW0.99930.8053715
PKD1-PIEZO1chr162155865chr16888028168072HLA-B18:06NEVWSITY0.99930.76421119
PKD1-PIEZO1chr162155865chr16888028168072HLA-B57:02VTVLNEVW0.99860.961715
PKD1-PIEZO1chr162155865chr16888028168072HLA-B18:03NEVWSITY0.99840.74541119
PKD1-PIEZO1chr162155865chr16888028168072HLA-B18:11NEVWSITY0.98230.69221119
PKD1-PIEZO1chr162155865chr16888028168072HLA-B35:20NEVWSITY0.89720.85211119
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:03ALVTVLNEV0.99830.8229514
PKD1-PIEZO1chr162155865chr16888028168072HLA-B57:04LVTVLNEVW0.99650.8574615
PKD1-PIEZO1chr162155865chr16888028168072HLA-B57:10LVTVLNEVW0.99550.9933615
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:06ALVTVLNEV0.99530.8117514
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:14ALVTVLNEV0.99520.7927514
PKD1-PIEZO1chr162155865chr16888028168072HLA-B18:08NEVWSITYH0.99090.66391120
PKD1-PIEZO1chr162155865chr16888028168072HLA-B18:05NEVWSITYH0.99090.85321120
PKD1-PIEZO1chr162155865chr16888028168072HLA-B18:06NEVWSITYH0.99050.85751120
PKD1-PIEZO1chr162155865chr16888028168072HLA-B57:02LVTVLNEVW0.98520.9757615
PKD1-PIEZO1chr162155865chr16888028168072HLA-A68:02TVLNEVWSI0.98420.668817
PKD1-PIEZO1chr162155865chr16888028168072HLA-A69:01TVLNEVWSI0.98070.7381817
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:14TVLNEVWSI0.97360.5458817
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:06TVLNEVWSI0.97230.6294817
PKD1-PIEZO1chr162155865chr16888028168072HLA-B18:03NEVWSITYH0.96650.84211120
PKD1-PIEZO1chr162155865chr16888028168072HLA-B15:13LVTVLNEVW0.93990.9561615
PKD1-PIEZO1chr162155865chr16888028168072HLA-A32:01TVLNEVWSI0.91240.9158817
PKD1-PIEZO1chr162155865chr16888028168072HLA-B18:11NEVWSITYH0.78660.81861120
PKD1-PIEZO1chr162155865chr16888028168072HLA-B53:02LVTVLNEVW0.77790.8076615
PKD1-PIEZO1chr162155865chr16888028168072HLA-B15:27VLNEVWSITY0.99970.8276919
PKD1-PIEZO1chr162155865chr16888028168072HLA-B15:125VLNEVWSITY0.99970.8263919
PKD1-PIEZO1chr162155865chr16888028168072HLA-B15:135VLNEVWSITY0.99970.8316919
PKD1-PIEZO1chr162155865chr16888028168072HLA-B15:50VLNEVWSITY0.99970.9275919
PKD1-PIEZO1chr162155865chr16888028168072HLA-B15:34VLNEVWSITY0.99970.8263919
PKD1-PIEZO1chr162155865chr16888028168072HLA-B15:33VLNEVWSITY0.99970.8263919
PKD1-PIEZO1chr162155865chr16888028168072HLA-B15:12VLNEVWSITY0.99960.8678919
PKD1-PIEZO1chr162155865chr16888028168072HLA-B15:35VLNEVWSITY0.9990.793919
PKD1-PIEZO1chr162155865chr16888028168072HLA-B15:24VLNEVWSITY0.99880.7836919
PKD1-PIEZO1chr162155865chr16888028168072HLA-B57:10EVWSITYHSW0.99730.95681222
PKD1-PIEZO1chr162155865chr16888028168072HLA-B15:24ALVTVLNEVW0.99440.9762515
PKD1-PIEZO1chr162155865chr16888028168072HLA-B15:39VLNEVWSITY0.99190.7676919
PKD1-PIEZO1chr162155865chr16888028168072HLA-B57:04EVWSITYHSW0.9910.62941222
PKD1-PIEZO1chr162155865chr16888028168072HLA-A25:01EVWSITYHSW0.95890.76771222
PKD1-PIEZO1chr162155865chr16888028168072HLA-B15:20VLNEVWSITY0.94420.9072919
PKD1-PIEZO1chr162155865chr16888028168072HLA-B15:13EVWSITYHSW0.92950.62731222
PKD1-PIEZO1chr162155865chr16888028168072HLA-B35:28VLNEVWSITY0.92190.902919
PKD1-PIEZO1chr162155865chr16888028168072HLA-B35:20VLNEVWSITY0.90080.9096919
PKD1-PIEZO1chr162155865chr16888028168072HLA-B15:13VLNEVWSITY0.85260.5674919
PKD1-PIEZO1chr162155865chr16888028168072HLA-B57:10LALVTVLNEVW0.99980.9894415
PKD1-PIEZO1chr162155865chr16888028168072HLA-B44:13NEVWSITYHSW0.99970.9421122
PKD1-PIEZO1chr162155865chr16888028168072HLA-B44:07NEVWSITYHSW0.99970.9421122
PKD1-PIEZO1chr162155865chr16888028168072HLA-B44:26NEVWSITYHSW0.99970.9421122
PKD1-PIEZO1chr162155865chr16888028168072HLA-A02:03SLALVTVLNEV0.99720.9211314

Top

Potential FusionNeoAntigen Information of PKD1-PIEZO1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of PKD1-PIEZO1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
5803LVTVLNEVWSITYHPKD1PIEZO1chr162155865chr16888028168072

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of PKD1-PIEZO1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN5803LVTVLNEVWSITYH-7.15543-7.26883
HLA-B14:023BVN5803LVTVLNEVWSITYH-4.77435-5.80965
HLA-B52:013W395803LVTVLNEVWSITYH-6.80875-6.92215
HLA-B52:013W395803LVTVLNEVWSITYH-4.20386-5.23916
HLA-A11:014UQ25803LVTVLNEVWSITYH-7.5194-8.5547
HLA-A11:014UQ25803LVTVLNEVWSITYH-6.9601-7.0735
HLA-A24:025HGA5803LVTVLNEVWSITYH-7.52403-7.63743
HLA-A24:025HGA5803LVTVLNEVWSITYH-5.82433-6.85963
HLA-B27:056PYJ5803LVTVLNEVWSITYH-3.28285-4.31815
HLA-B44:053DX85803LVTVLNEVWSITYH-5.91172-6.94702
HLA-B44:053DX85803LVTVLNEVWSITYH-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of PKD1-PIEZO1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
PKD1-PIEZO1chr162155865chr16888028161119NEVWSITYAACGAGGTATGGAGCATCACCTAC
PKD1-PIEZO1chr162155865chr16888028161120NEVWSITYHAACGAGGTATGGAGCATCACCTACCAC
PKD1-PIEZO1chr162155865chr16888028161122NEVWSITYHSWAACGAGGTATGGAGCATCACCTACCACAGCTGG
PKD1-PIEZO1chr162155865chr16888028161222EVWSITYHSWGAGGTATGGAGCATCACCTACCACAGCTGG
PKD1-PIEZO1chr162155865chr1688802816314SLALVTVLNEVTCGTTGGCCCTGGTCACCGTGCTGAACGAGGTA
PKD1-PIEZO1chr162155865chr1688802816415LALVTVLNEVWTTGGCCCTGGTCACCGTGCTGAACGAGGTATGG
PKD1-PIEZO1chr162155865chr1688802816514ALVTVLNEVGCCCTGGTCACCGTGCTGAACGAGGTA
PKD1-PIEZO1chr162155865chr1688802816515ALVTVLNEVWGCCCTGGTCACCGTGCTGAACGAGGTATGG
PKD1-PIEZO1chr162155865chr1688802816615LVTVLNEVWCTGGTCACCGTGCTGAACGAGGTATGG
PKD1-PIEZO1chr162155865chr1688802816715VTVLNEVWGTCACCGTGCTGAACGAGGTATGG
PKD1-PIEZO1chr162155865chr1688802816817TVLNEVWSIACCGTGCTGAACGAGGTATGGAGCATC
PKD1-PIEZO1chr162155865chr1688802816919VLNEVWSITYGTGCTGAACGAGGTATGGAGCATCACCTAC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of PKD1-PIEZO1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
STADPKD1-PIEZO1chr162155865ENST00000262304chr1688802816ENST00000301015TCGA-VQ-AA69

Top

Potential target of CAR-T therapy development for PKD1-PIEZO1

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
TgenePIEZO1chr16:2155865chr16:88802816ENST0000030101510511043_106302522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST0000030101510511160_118002522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST0000030101510511184_120402522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST0000030101510511218_124002522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST0000030101510511247_126402522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST0000030101510511277_129702522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST0000030101510511678_169802522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST0000030101510511700_172002522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST0000030101510511734_175402522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST0000030101510511962_198202522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST0000030101510512003_202302522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST0000030101510512032_205202522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST0000030101510512061_208102522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST0000030101510512100_212202522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST0000030101510512129_214902522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST0000030101510512177_219702522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST0000030101510512432_245202522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST000003010151051460_48002522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST000003010151051514_53402522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST000003010151051579_59902522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST000003010151051602_62202522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST000003010151051629_64902522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST000003010151051681_70102522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST000003010151051823_84302522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST000003010151051852_87202522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST000003010151051926_94602522.0TransmembraneHelical
TgenePIEZO1chr16:2155865chr16:88802816ENST000003010151051987_100702522.0TransmembraneHelical

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result
PKD1chr162155865ENST00000262304PIEZO1chr1688802816ENST00000301015

Top

Related Drugs to PKD1-PIEZO1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to PKD1-PIEZO1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource